In this report,global Bio Pharma Buffer Market will reach 929.47 Million USD by the end of 2022 with a CAGR of 7.81%
The global Bio Pharma Buffer market was valued at 638.29 Million USD in 2017 and will reach 929.47 Million USD by the end of 2022, growing at a CAGR of 7.81% during 2017-2022.
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Bio Pharma Buffer can be divided into four categories: Phosphates Type, Acetates Type and TRIS Type. Phosphates Type accounted for the highest proportion in revenue market, with a figure of 28.68% in 2017, followed by TRIS Type, account for 22.65% and Acetates Type account for 13.33%.
The sales market share of global Bio Pharma Buffer in Research Institution use, \Pharmaceutical Industry use and other applictions have been stable year by year, at 42.10%, 50.48% and 7.42% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Bio Pharma Buffer in the global market tends to be fixed without great changes. Among them, the Bio Pharma Buffer market has the most promising sales prospects in Pharmaceutical Industry use.
XYZ research center data shows that North America is the biggest contributor to the Bio Pharma Buffer revenue market, accounted for 47.35% of the total global market with a revenue of 302.21 million USD in 2017, followed by Europe, 27.90% with a revenue of 178.10 million USD.
Merck is the largest company in the global Bio Pharma Buffer market, accounted for 20.82% of the revenue market share in 2017, followed by Avantor and Alfa Aesar (Thermo Fisher), accounted for 18.19% and 16.45% of the revenue market share in 2017. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share in 2016.
Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Bio Pharma Buffer for these regions, from 2014 to 2026 (forecast), covering
Global Bio Pharma Buffer market competition by top manufacturers/players, with Bio Pharma Buffer sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Alfa Aesar (Thermo Fisher)
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Bio Pharma Buffer for each application, including
If you have any special requirements, please let us know and we will offer you the report as you want.